The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
Open accessAbstract
Nucleic acid-based therapeutics that regulate gene expression have been developed towards clinical use at a steady pace for several decades, but in recent years the field has been accelerating. To date, there are 11 marketed products based on antisense oligonucleotides, aptamers and small interfering RNAs, and many others are in the pipeline for both academia and industry. A major technology trigger for this development has been progress in oligonucleotide chemistry to improve the drug properties and reduce cost of goods, but the main hurdle for the application to a wider range of disorders is delivery to target tissues. The adoption of delivery technologies, such as conjugates or nanoparticles, has been a game changer for many therapeutic indications, but many others are still awaiting their eureka moment. Here, we cover the variety of methods developed to deliver nucleic acid-based therapeutics across biological barriers and the model systems used to test them. We discuss important safety considerations and regulatory requirements for synthetic oligonucleotide chemistries and the hurdles for translating laboratory breakthroughs to the clinic. Recent advances in the delivery of nucleic acid-based therapeutics and in the development of model systems, as well as safety considerations and regulatory requirements for synthetic oligonucleotide chemistries are discussed in this review on oligonucleotide-based therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429 · cited 2×
“Patisiran represents an important milestone, because it is the first marketed drug based on siRNA, launched only 20 years after the discovery of the RNAi mechanism (Fire et al, 1998).”
BackgroundGenome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
Most mammalian mRNAs are conserved targets of microRNAs
Friedman, R. C., Farh, K. K.-H., Burge, C. B., & Bartel, D. P. (2009) · Genome Research · doi:10.1101/gr.082701.108 · Cited by 8,462
Alginate: Properties and biomedical applications
Lee, K. Y., & Mooney, D. J. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.06.003 · Cited by 8,095
Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.
Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., & Danielsen, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7413 · Cited by 4,978
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1807 · Cited by 4,930 · cited 7×
“The most frequently used CNS administration route in humans is intrathecal (IT) administration, where ONs are administered into the subarachnoid space of the spinal cord to pass the pia mater and enter the parenchyma.”
BackgroundInfluentialReconstituting organ-level lung functions on a chip
Huh, D., Matthews, B. D., Mammoto, A., Montoya-Zavala, M., Hsin, H. Y., & Ingber, D. E. (2010) · Science · doi:10.1126/science.1188302 · Cited by 4,250 · cited 2×
“Organ-on-chips reproduce the interaction between cultures of multiple tissue types using microfluidic channels and chambers (Huh et al, 2010; Kim et al, 2012; Westein et al, 2013).”
BackgroundSequence-Selective Recognition of DNA by Strand Displacement with a Thymine-Substituted Polyamide
Nielsen, P. E., Egholm, M., Berg, R. H., & Buchardt, O. (1991) · Science · doi:10.1126/science.1962210 · Cited by 3,332 · cited 10×
“Both PMO and PNA are uncharged, very resistant to nucleases, and display variable affinity for the target RNA (Smulevitch et al, 1996; Summerton & Weller, 1997).”
BackgroundInfluentialPatisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Reassessment of exosome composition
Jeppesen, D. K., Fenix, A. M., Franklin, J. L., Higginbotham, J. N., Zhang, Q., Zimmerman, L. J., Liebler, D. C., Ping, J., Liu, Q., Evans, R., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.029 · Cited by 2,975 · cited 1×
“Additionally, exosome heterogeneity is caused by their natural content of proteins and nucleic acids derived from the host cell (Willms et al, 2018; Jeppesen et al, 2019).”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702752 · Cited by 2,337
Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics
Jayasena, S. D. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.9.1628 · Cited by 2,144
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,027
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Zamecnik, P. C., & Stephenson, M. L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.1.280 · Cited by 1,792
Kim, H. J., Huh, D., Hamilton, G., & Ingber, D. E. (2012) · Lab on a Chip · doi:10.1039/c2lc40074j · Cited by 1,734
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Ng, E. W. M., Shima, D. T., Calias, P., Cunningham, E. T., Guyer, D. R., & Adamis, A. P. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1955 · Cited by 1,588
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261 · cited 1×
“In addition, active hepatocyte targeting has been shown to occur via surface adsorption of apolipoprotein E, which targets the LNPs to the internalising low-density lipoprotein receptor expressed on hepatocytes (Akinc et al, 2010; Chen et al, 2016).”
BackgroundTherapeutic potential of Toll-like receptor 9 activation
Krieg, A. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,246
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E. S., Busini, V., Hossain, N., Bacallado, S. A., Nguyen, D. N., Fuller, J., Alvarez, R., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1402 · Cited by 1,150
Morpholino Antisense Oligomers: Design, Preparation, and Properties
SUMMERTON, J., & WELLER, D. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.187 · Cited by 1,116
Koshkin, A. A., Singh, S. K., Nielsen, P., Rajwanshi, V. K., Kumar, R., Meldgaard, M., Olsen, C. E., & Wengel, J. (1998) · Tetrahedron · doi:10.1016/s0040-4020(98)00094-5 · Cited by 1,047
Advances in therapeutic applications of extracellular vesicles
Wiklander, O. P. B., Brennan, M. Á., Lötvall, J., Breakefield, X. O., & EL Andaloussi, S. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav8521 · Cited by 1,039
Exosomes: Therapy delivery tools and biomarkers of diseases
Barile, L., & Vassalli, G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.020 · Cited by 1,038
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Willms, E., Cabañas, C., Mäger, I., Wood, M. J. A., & Vader, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00738 · Cited by 981
Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophy
Miller, J. W. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4439 · Cited by 937
Human Neuroblasts Migrate to the Olfactory Bulb via a Lateral Ventricular Extension
Curtis, M. A., Kam, M., Nannmark, U., Anderson, M. F., Axell, M. Z., Wikkelso, C., Holtås, S., van Roon-Mom, W. M. C., Björk-Eriksson, T., Nordborg, C., et al. (2007) · Science · doi:10.1126/science.1136281 · Cited by 890
Self-citationCirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
Self-citationPatient-Customized Oligonucleotide Therapy for a Rare Genetic Disease
Kim, J., Hu, C., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Lee, E. A., Kuniholm, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813279 · Cited by 827
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles
Pathan, M., Fonseka, P., Chitti, S. V., Kang, T., Sanwlani, R., Van Deun, J., Hendrix, A., & Mathivanan, S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1029 · Cited by 767
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Obika, S., Nanbu, D., Hari, Y., Andoh, J.-I., Morio, K.-I., Doi, T., & Imanishi, T. (1998) · Tetrahedron Letters · doi:10.1016/s0040-4039(98)01084-3 · Cited by 700
Phosphorothioates, Essential Components of Therapeutic Oligonucleotides
Eckstein, F. (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.0506 · Cited by 684 · cited 2×
“phosphorothioate (PS), which imparts resistance to endonucleases and improves bioavailability by reducing renal clearance due to increased affinity for serum proteins (Eckstein, 2014).”
BackgroundMutations in the CEP290 (NPHP6) Gene Are a Frequent Cause of Leber Congenital Amaurosis
den Hollander, A. I., Koenekoop, R. K., Yzer, S., Lopez, I., Arends, M. L., Voesenek, K. E. J., Zonneveld, M. N., Strom, T. M., Meitinger, T., Brunner, H. G., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/507318 · Cited by 668
PLGA-Based Nanoparticles in Cancer Treatment
Rezvantalab, S., Drude, N. I., Moraveji, M. K., Güvener, N., Koons, E. K., Shi, Y., Lammers, T., & Kiessling, F. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01260 · Cited by 607
Cellular uptake and trafficking of antisense oligonucleotides
Crooke, S. T., Wang, S., Vickers, T. A., Shen, W., & Liang, X.-H. (2017) · Nature Biotechnology · doi:10.1038/nbt.3779 · Cited by 582 · cited 1×
“ONs are subsequently trafficked into the endolysosomal system, from where they need to escape to avoid degradation in the lysosomal environment (Crooke et al, 2017).”
BackgroundDesign of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Antisense and Antigene Properties of Peptide Nucleic Acids
Hanvey, J. C., Peffer, N. J., Bisi, J. E., Thomson, S. A., Cadilla, R., Josey, J. A., Ricca, D. J., Hassman, C. F., Bonham, M. A., Au, K. G., et al. (1992) · Science · doi:10.1126/science.1279811 · Cited by 533
Gold Nanoparticles for Nucleic Acid Delivery
Ding, Y., Jiang, Z., Saha, K., Kim, C. S., Kim, S. T., Landis, R. F., & Rotello, V. M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.30 · Cited by 521
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Wahlestedt, C., Salmi, P., Good, L., Kela, J., Johnsson, T., Hökfelt, T., Broberger, C., Porreca, F., Lai, J., Ren, K., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5633 · Cited by 520
Off-target effects by siRNA can induce toxic phenotype
Fedorov, Y., Anderson, E. M., Birmingham, A., Reynolds, A., Karpilow, J., Robinson, K., Leake, D., Marshall, W. S., & Khvorova, A. (2006) · RNA · doi:10.1261/rna.28106 · Cited by 490
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates
Dong, Y., Love, K. T., Dorkin, J. R., Sirirungruang, S., Zhang, Y., Chen, D., Bogorad, R. L., Yin, H., Chen, Y., Vegas, A. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1322937111 · Cited by 488 · cited 1×
“These include, among others, lipidoids (Akinc et al, 2008; Dong et al, 2014) and the ionisable lipid DLin-MC3-DMA (Jayaraman et al, 2012), which is considered the gold standard of ionisable cationic lipids.”
BackgroundSemple, S. C., Klimuk, S. K., Harasym, T. O., Dos Santos, N., Ansell, S. M., Wong, K. F., Maurer, N., Stark, H., Cullis, P. R., Hope, M. J., et al. (2001) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(00)00343-6 · Cited by 454
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Chemically modified siRNA: tools and applications
Watts, J. K., Deleavey, G. F., & Damha, M. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.05.007 · Cited by 431
Pharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Delivery of oligonucleotides to the liver with GalNAc: From research to registered therapeutic drug.
Debacker, A. J., Voutila, J., Catley, M., Blakey, D., & Habib, N. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.015 · Cited by 424
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges
Yu, A.-M., Choi, Y. H., & Tu, M.-J. (2020) · Pharmacological Reviews · doi:10.1124/pr.120.019554 · Cited by 395
Achberger, K., Probst, C., Haderspeck, J., Bolz, S., Rogal, J., Chuchuy, J., Nikolova, M., Cora, V., Antkowiak, L., Haq, W., et al. (2019) · eLife · doi:10.7554/elife.46188 · Cited by 380
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA
Chen, S., Tam, Y. Y. C., Lin, P. J. C., Sung, M. M. H., Tam, Y. K., & Cullis, P. R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.059 · Cited by 366
Stein, C. A., Hansen, J. B., Lai, J., Wu, S., Voskresenskiy, A., H⊘g, A., Worm, J., Hedtjärn, M., Souleimanian, N., Miller, P., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkp841 · Cited by 360
Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs
Wu, H., Lima, W. F., Zhang, H., Fan, A., Sun, H., & Crooke, S. T. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311683200 · Cited by 349
Shen, W., De Hoyos, C. L., Migawa, M. T., Vickers, T. A., Sun, H., Low, A., Bell, T. A., Rahdar, M., Mukhopadhyay, S., Hart, C. E., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0106-2 · Cited by 345
Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623314551840 · Cited by 334
Microfluidic organ-on-chip technology for blood-brain barrier research
van der Helm, M. W., van der Meer, A. D., Eijkel, J. C. T., van den Berg, A., & Segerink, L. I. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1142493 · Cited by 333
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321 · cited 1×
“The recent approval of patisiran (Table 3) (Suhr et al, 2015), together with improvements in manufacturability brought about by the introduction of microfluidics, has reinforced interest in lipidbased delivery systems to the scientific community and pharmaceutical industry.”
BackgroundHeo, Y.-A. (2020) · Drugs · doi:10.1007/s40265-020-01267-2 · Cited by 317
Organs-on-chips: breaking the in vitro impasse
Meer, A. D. V. D., & Berg, A. V. D. (2012) · Integrative Biology · doi:10.1039/c2ib00176d · Cited by 314
Voit, T., Topaloglu, H., Straub, V., Muntoni, F., Deconinck, N., Campion, G., De Kimpe, S. J., Eagle, M., Guglieri, M., Hood, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70195-4 · Cited by 306
Westein, E., van der Meer, A. D., Kuijpers, M. J. E., Frimat, J.-P., van den Berg, A., & Heemskerk, J. W. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209905110 · Cited by 304
Parfitt, D. A., Lane, A., Ramsden, C. M., Carr, A.-J. F., Munro, P. M., Jovanovic, K., Schwarz, N., Kanuga, N., Muthiah, M. N., Hull, S., et al. (2016) · Cell Stem Cell · doi:10.1016/j.stem.2016.03.021 · Cited by 301
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 300
Safety of antisense oligonucleotide and siRNA-based therapeutics
Chi, X., Gatti, P., & Papoian, T. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.013 · Cited by 280
Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity
Janas, M. M., Schlegel, M. K., Harbison, C. E., Yilmaz, V. O., Jiang, Y., Parmar, R., Zlatev, I., Castoreno, A., Xu, H., Shulga-Morskaya, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02989-4 · Cited by 279 · cited 2×
“This high affinity-binding ligand has been directly conjugated to ONs and siRNA and provides highly specific and effective delivery to hepatocytes (Matsuda et al, 2015; Janas et al, 2018; Debacker et al, 2020).”
BackgroundAntisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
Schoch, K. M., & Miller, T. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.010 · Cited by 274 · cited 1×
“Animal models have been vital for determining in vivo efficacy of ONs, tissue-specific delivery, and optimising the route of administration for systemic and neurological diseases (Schoch & Miller, 2017; Buijsen et al, 2019).”
BackgroundPhase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria
Sardh, E., Harper, P., Balwani, M., Stein, P., Rees, D., Bissell, D. M., Desnick, R., Parker, C., Phillips, J., Bonkovsky, H. L., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1807838 · Cited by 259
Stein, H., & Hausen, P. (1969) · Science · doi:10.1126/science.166.3903.393 · Cited by 257
Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245 · cited 1×
“In clinical trials, inflammatory adverse effects may manifest as flu-like symptoms and injection site reactions following subcutaneous (SC) administration (Rudin et al, 2001; Thomas et al, 2013; Voit et al, 2014).”
BackgroundDelivery of therapeutic oligonucleotides with cell penetrating peptides
Boisguérin, P., Deshayes, S., Gait, M. J., O'Donovan, L., Godfrey, C., Betts, C. A., Wood, M. J. A., & Lebleu, B. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.02.008 · Cited by 245
Cideciyan, A. V., Jacobson, S. G., Drack, A. V., Ho, A. C., Charng, J., Garafalo, A. V., Roman, A. J., Sumaroka, A., Han, I. C., Hochstedler, M. D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0295-0 · Cited by 222
(2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(02)01327-2 · Cited by 222
Matsuda, S., Keiser, K., Nair, J. K., Charisse, K., Manoharan, R. M., Kretschmer, P., Peng, C. G., V. Kel’in, A., Kandasamy, P., Willoughby, J. L. S., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501028c · Cited by 221
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Sugo, T., Terada, M., Oikawa, T., Miyata, K., Nishimura, S., Kenjo, E., Ogasawara-Shimizu, M., Makita, Y., Imaichi, S., Murata, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.036 · Cited by 221
Peptides for nucleic acid delivery
Lehto, T., Ezzat, K., Wood, M. J. A., & EL Andaloussi, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.008 · Cited by 220
Self-citationDhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01339-3 · Cited by 218
Burel, S. A., Hart, C. E., Cauntay, P., Hsiao, J., Machemer, T., Katz, M., Watt, A., Bui, H.-H., Younis, H., Sabripour, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1210 · Cited by 216
Liang, X.-H., Shen, W., Sun, H., Migawa, M. T., Vickers, T. A., & Crooke, S. T. (2016) · Nature Biotechnology · doi:10.1038/nbt.3589 · Cited by 212
Haché, M., Swoboda, K. J., Sethna, N., Farrow-Gillespie, A., Khandji, A., Xia, S., & Bishop, K. M. (2016) · Journal of Child Neurology · doi:10.1177/0883073815627882 · Cited by 208
Cell-penetrating peptides for drug delivery across membrane barriers
Foged, C., & Nielsen, H. M. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.105 · Cited by 205
Self-citationYang, T., Fogarty, B., LaForge, B., Aziz, S., Pham, T., Lai, L., & Bai, S. (2017) · The AAPS Journal · doi:10.1208/s12248-016-0015-y · Cited by 204
Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., & Kornbrust, D. J. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36667-4 · Cited by 204
Aartsma-Rus, A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0665 · Cited by 196
Self-citationHammond, S. M., Hazell, G., Shabanpoor, F., Saleh, A. F., Bowerman, M., Sleigh, J. N., Meijboom, K. E., Zhou, H., Muntoni, F., Talbot, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1605731113 · Cited by 193
Self-citationTargeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis
Yao, Y.-D., Sun, T.-M., Huang, S.-Y., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C.-Q., Yu, F.-Y., Zeng, M.-S., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 188
Targeted delivery of antisense oligonucleotides to pancreatic β-cells
Ämmälä, C., Drury, W. J., Knerr, L., Ahlstedt, I., Stillemark-Billton, P., Wennberg-Huldt, C., Andersson, E.-M., Valeur, E., Jansson-Löfmark, R., Janzén, D., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat3386 · Cited by 188
Oligonucleotide Therapeutics — A New Class of Cholesterol-Lowering Drugs
Khvorova, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmp1614154 · Cited by 183
New synthetic cluster ligands for galactose/N-acetylgalactosamine-specific lectin of mammalian liver
Lee, R. T., Lin, P., & Lee, Y. C. (1984) · Biochemistry · doi:10.1021/bi00313a037 · Cited by 180
Burdick, A. D., Sciabola, S., Mantena, S. R., Hollingshead, B. D., Stanton, R., Warneke, J. A., Zeng, M., Martsen, E., Medvedev, A., Makarov, S. S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku142 · Cited by 178
Heemskerk, H. A., de Winter, C. L., de Kimpe, S. J., van Kuik‐Romeijn, P., Heuvelmans, N., Platenburg, G. J., van Ommen, G. B., van Deutekom, J. C. T., & Aartsma‐Rus, A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1288 · Cited by 173
Self-citationFirst "Antisense" Drug Will Treat CMV Retinitis
Marwick, C. (1998) · JAMA · doi:10.1001/jama.280.10.871-jmn0909-6-1 · Cited by 167
Delivery is key: lessons learnt from developing splice‐switching antisense therapies
Godfrey, C., Desviat, L. R., Smedsrød, B. H., Piétri‐Rouxel, F., Denti, M. A., Disterer, P., Lorain, S., Nogales‐Gadea, G., Sardone, V., Anwar, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607199 · Cited by 166
Self-citationGeary, R. S., Baker, B. F., & Crooke, S. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0224-4 · Cited by 165
Jaax, M. E., Krauel, K., Marschall, T., Brandt, S., Gansler, J., Fürll, B., Appel, B., Fischer, S., Block, S., Helm, C. A., et al. (2013) · Blood · doi:10.1182/blood-2013-01-478966 · Cited by 162
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Prakash, T. P., Mullick, A. E., Lee, R. G., Yu, J., Yeh, S. T., Low, A., Chappell, A. E., Østergaard, M. E., Murray, S., Gaus, H. J., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz354 · Cited by 162
Fusion-dependent formation of lipid nanoparticles containing macromolecular payloads
Kulkarni, J. A., Witzigmann, D., Leung, J., van der Meel, R., Zaifman, J., Darjuan, M. M., Grisch-Chan, H. M., Thöny, B., Tam, Y. Y. C., & Cullis, P. R. (2019) · Nanoscale · doi:10.1039/c9nr02004g · Cited by 161
Fomivirsen: Clinical Pharmacology and Potential Drug Interactions
Geary, R. S., Henry, S. P., & Grillone, L. R. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241040-00002 · Cited by 160
Osborn, M. F., Coles, A. H., Biscans, A., Haraszti, R. Á., Roux, L., Davis, S. M., Ly, S., Echeverria, D., Hassler, M. R., Godinho, B. M. D. C., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1232 · Cited by 159
Liang, X., Sun, H., Shen, W., Wang, S., Yao, J., Migawa, M. T., Bui, H., Damle, S. S., Riney, S., Graham, M. J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx632 · Cited by 158
Collin, R. W. J., den Hollander, A. I., van der Velde-Visser, S. D., Bennicelli, J. L., Bennett, J., & Cremers, F. P. M. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.3 · Cited by 152
Self-citationHenry, S. P., Beattie, G., Yeh, G., Chappel, A., Giclas, P. C., Mortari, A., Jagels, M. A., Kornbrust, D. J., & Levin, A. A. (2002) · International Immunopharmacology · doi:10.1016/s1567-5769(02)00142-x · Cited by 151
Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
Buijsen, R. A. M., Toonen, L. J. A., Gardiner, S. L., & van Roon‐Mom, W. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00696-y · Cited by 151
Self-citationMultiscale reverse engineering of the human ocular surface
Seo, J., Byun, W. Y., Alisafaei, F., Georgescu, A., Yi, Y., Massaro‐Giordano, M., Shenoy, V. B., Lee, V., Bunya, V. Y., & Huh, D. (2019) · Nature Medicine · doi:10.1038/s41591-019-0531-2 · Cited by 149
Vollmer, J., Weeratna, R. D., Jurk, M., Samulowitz, U., McCluskie, M. J., Payette, P., Davis, H. L., Schetter, C., & Krieg, A. Μ. (2004) · Immunology · doi:10.1111/j.1365-2567.2004.01962.x · Cited by 146
Antisense and siRNA as agonists of Toll-like receptors
Agrawal, S., & Kandimalla, E. R. (2004) · Nature Biotechnology · doi:10.1038/nbt1042 · Cited by 144
Heemskerk, H., de Winter, C., van Kuik‐Romeijn, P., Heuvelmans, N., Sabatelli, P., Rimessi, P., Braghetta, P., van Ommen, G. B., de Kimpe, S. J., Ferlini, A., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.72 · Cited by 141
Self-citationGaranto, A., Chung, D. C., Duijkers, L., Corral-Serrano, J. C., Messchaert, M., Xiao, R., Bennett, J., Vandenberghe, L. H., & Collin, R. W. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw118 · Cited by 141
Self-citationA pumpless multi‐organ‐on‐a‐chip (MOC) combined with a pharmacokinetic–pharmacodynamic (PK–PD) model
Lee, H., Kim, D. S., Ha, S. K., Choi, I., Lee, J. M., & Sung, J. H. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26087 · Cited by 137
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy
Aartsma-Rus, A. M., & Corey, D. R. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0845 · Cited by 135
Self-citationWong, E., & Goldberg, T. (2014) · Europe PMC (PubMed Central) · Cited by 134
Aptamer-Mediated Targeted Delivery of Therapeutics: An Update
Catuogno, S., Esposito, C. L., & de Franciscis, V. (2016) · Pharmaceuticals · doi:10.3390/ph9040069 · Cited by 134
Accessing the therapeutic potential of immunostimulatory nucleic acids
Barchet, W., Wimmenauer, V., Schlee, M., & Hartmann, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.07.007 · Cited by 129
Rudin, C. M., Holmlund, J. T., Fleming, G. F., Mani, S., Stadler, W. M., Schumm, L. P., Monia, B. P., Johnston, J. F., Geary, R. S., Yu, R. Z., et al. (2001) · PubMed · Cited by 129
Shi, B., Keough, E., Matter, A., Leander, K., Young, S., Carlini, E., Sachs, A. B., Tao, W., Abrams, M., Howell, B., et al. (2011) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155411410885 · Cited by 125 · cited 1×
“The LNPs are passively targeted to the liver (Shi et al, 2011), and the size of the LNPs permits delivery through the fenestrated endothelium in the liver to the underlying hepatocytes (Chen et al, 2016).”
BackgroundDifficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte.
Schwartz, A. L., Rup, D., & Lodish, H. F. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70522-5 · Cited by 125
Yu, R. Z., Lemonidis, K. M., Graham, M. J., Matson, J. E., Crooke, R. M., Tribble, D. L., Wedel, M. K., Levin, A. A., & Geary, R. S. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.005 · Cited by 125
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents.
Monteith, D. K. B., Henry, S. P., Rb, H., et al. (1997) · PubMed · Cited by 124
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide
Henry, S. P., Novotny, W. F., LEEDS, J., Auletta, C. S., & Kornbrust, D. J. (1997) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.1997.7.503 · Cited by 122
Managing the sequence-specificity of antisense oligonucleotides in drug discovery
Hagedorn, P., Hansen, B. R., Koch, T., & Lindow, M. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx056 · Cited by 119
Phosphorothioate Oligonucleotides Inhibit the Intrinsic Tenase Complex
Sheehan, J. P., & Lan, H.-C. (1998) · Blood · doi:10.1182/blood.v92.5.1617 · Cited by 118
Inhaled RNA Therapy: From Promise to Reality
Chow, M. Y. T., Qiu, Y., & Lam, J. K. W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.002 · Cited by 117
THE VEGF INHIBITION STUDY IN OCULAR NEOVASCULARIZATION (V.I.S.I.O.N.) CLINICAL TRIAL GROUP (2005) · Retina · doi:10.1097/00006982-200510000-00001 · Cited by 116
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators
Flierl, U., Nero, T. L., Lim, B., Arthur, J. F., Yao, Y., Jung, S. M., Gitz, E., Pollitt, A. Y., Zaldivia, M. T. K., Jandrot-Perrus, M., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140391 · Cited by 114 · cited 1×
“Direct activation of platelets by PS-ONs through the binding to platelet receptors has been demonstrated (Flierl et al, 2015; Sewing et al, 2017).”
BackgroundKlein, A. F., Varela, M. A., Arandel, L., Holland, A., Naouar, N., Arzumanov, A. A., Seoane, D., Revillod, L., Bassez, G., Ferry, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128205 · Cited by 113
Assessing unintended hybridization-induced biological effects of oligonucleotides
Lindow, M., Vornlocher, H., Riley, D. E., Kornbrust, D. J., Burchard, J., Whiteley, L. O., Kamens, J., Thompson, J. D., Nochur, S. V., Younis, H. S., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2376 · Cited by 111
McAleer, C. W., Pointon, A., Long, C. J., Brighton, R. L., Wilkin, B. D., Bridges, L. R., Sriram, N. N., Fabre, K. M., McDougall, R., Muse, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45656-4 · Cited by 105
Penichet, M. L., Kang, Y., Pardridge, W. M., Morrison, S. L., & Shin, S.-U. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4421 · Cited by 104
Antiinfective Applications of Toll-like Receptor 9 Agonists
KRIEG, A. M. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200701-021aw · Cited by 104
A Chemical View of Oligonucleotides for Exon Skipping and Related Drug Applications
Järver, P., O’Donovan, L., & Gait, M. J. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2013.0454 · Cited by 102
Cleal, K., He, L., Watson, P., & Jones, A. T. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990297 · Cited by 101
Inorganic nanomaterials as delivery systems for proteins, peptides, DNA, and siRNA
Malmsten, M. (2013) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2013.06.002 · Cited by 98
Goemans, N., Tulinius, M., van den Hauwe, M., Kroksmark, A., Buyse, G., Wilson, R. J., van Deutekom, J. C., de Kimpe, S. J., Lourbakos, A., & Campion, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161955 · Cited by 96
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Mathew, V., & Wang, A. K. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s162913 · Cited by 95
Optimizing synthetic nucleic acid and protein nanocarriers: The chemical evolution approach
Freitag, F., & Wagner, E. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.005 · Cited by 92
Habrant, D., Peuziat, P., Colombani, T., Dallet, L., Gehin, J., Emilie, G., Berangere, E., Lambert, O., Haudebourg, T., & Pitard, B. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01679 · Cited by 91
Antiviral Effects of Antisense Morpholino Oligomers in Murine Coronavirus Infection Models
Burrer, R., Neuman, B. W., Ting, J. P., Stein, D. A., Moulton, H. M., Iversen, P. L., Kühn, P., & Buchmeier, M. J. (2007) · Journal of Virology · doi:10.1128/jvi.02360-06 · Cited by 88
Senn, J. J., Burel, S. A., & Henry, S. P. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084004 · Cited by 88
A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells
Esposito, C. L., Nuzzo, S., Kumar, S. A., Rienzo, A., Lawrence, C. L., Pallini, R., Shaw, L., Alder, J. E., Ricci‐Vitiani, L., Catuogno, S., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.032 · Cited by 88
In Vitro Testing for Direct Immunotoxicity: State of the Art
Lankveld, D. P. K., Loveren, H. V., Baken, K. A., et al. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-401-2_26 · Cited by 86
Cha, W., Fan, R., Miao, Y., Zhou, Y., Qin, C., Shan, X., Wan, X., & Li, J. (2017) · Molecules · doi:10.3390/molecules22050782 · Cited by 85
Taetz, S., Nafee, N. A., Beisner, J., Piotrowska, K., Baldes, C., Mürdter, T. E., Huwer, H., Schneider, M., Schaefer, U. F., Klotz, U. E., et al. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.07.011 · Cited by 81
Classes of Cell-Penetrating Peptides
Pooga, M., & Langel, Ü. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2806-4_1 · Cited by 81
Liang, X., Shen, W., Sun, H., Kinberger, G. A., Prakash, T. P., Nichols, J. G., & Crooke, S. T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw144 · Cited by 79
Thanki, K., Zeng, X., Justesen, S., Tejlmann, S., Falkenberg, E., Driessche, E. V., Nielsen, H. M., Franzyk, H., & Foged, C. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.07.014 · Cited by 77
Self-citationDieckmann, A., Hagedorn, P., Burki, Y., Brügmann, C., Berrera, M., Ebeling, M., Singer, T., & Schuler, F. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.11.004 · Cited by 77
Du, L., Kayalı, R., Bertoni, C., Fike, F. M., Hu, H., Iversen, P. L., & Gatti, R. A. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr217 · Cited by 74
Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells
Wang, S., Allen, N., Prakash, T. P., Liang, X., & Crooke, S. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0794 · Cited by 73
Biscans, A., Caiazzi, J., Davis, S. M., McHugh, N., Sousa, J., & Khvorova, A. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa595 · Cited by 72
Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge
Smulevitch, S. V., Simmons, C. G., Norton, J. C., Wise, T. W., & Corey, D. R. (1996) · Nature Biotechnology · doi:10.1038/nbt1296-1700 · Cited by 70
The Effects of 2′- O -Methoxyethyl Oligonucleotides on Renal Function in Humans
Crooke, S. T., Baker, B. F., Pham, N. C., Hughes, S. G., Kwoh, T. J., Cai, D., Tsimikas, S., Geary, R. S., & Bhanot, S. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0693 · Cited by 69
Shinha, K., Nihei, W., Ono, T., Nakazato, R., & Kimura, H. (2020) · Biomicrofluidics · doi:10.1063/5.0011545 · Cited by 63
Selective delivery of therapeutic single strand antimiRs by aptamer-based conjugates
Catuogno, S., Rienzo, A., Vito, A. D., Esposito, C. L., & de Franciscis, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.276 · Cited by 62
Adsorption and Release of siRNA from Porous Silica
Steinbacher, J. L., & Landry, C. C. (2013) · Langmuir · doi:10.1021/la402850m · Cited by 61
McGregor, T. L., Hunt, K. A., Yee, E., Mason, D., Nioi, P., Ticau, S., Pelosi, M., Loken, P. R., Finer, S., Lawlor, D. A., et al. (2020) · eLife · doi:10.7554/elife.54363 · Cited by 61
Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
Szebeni, J. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.025 · Cited by 57
Lee, H. J., Boado, R. J., Braasch, D. A., Corey, D. R., & Pardridge, W. M. (2002) · PubMed · Cited by 56
Fußer, M., Øverbye, A., Pandya, A. D., Mørch, Y. A., Borgos, S. E., Kildal, W., Snipstad, S., Sulheim, E., Fleten, K. G., Askautrud, H. A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.029 · Cited by 56
Self-citationAptamer-iRNAs as Therapeutics for Cancer Treatment
Soldevilla, M. M., Meraviglia-Crivelli, D., Menon, A. P., & Pastor, F. (2018) · Pharmaceuticals · doi:10.3390/ph11040108 · Cited by 54
Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C. S., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570341 · Cited by 53
Sewing, S., Roth, A. B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., Ploix, C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187574 · Cited by 52
Toll-Like Receptor 9 Activation with CpG Oligodeoxynucleotides for Asthma Therapy*
Kline, J. N., & Krieg, A. Μ. (2008) · Drug News & Perspectives · doi:10.1358/dnp.2008.21.8.1272133 · Cited by 52
Rational Design of Antisense Oligomers to Induce Dystrophin Exon Skipping
Mitrpant, C., Adams, A. M., Meloni, P. L., Muntoni, F., Fletcher, S., & Wilton, S. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.49 · Cited by 52
Splicing modulation therapy in the treatment of genetic diseases
Aartsma-Rus, A. M., Arechavala‐Gomeza, V., & Khoo, B. C. E. (2014) · The Application of Clinical Genetics · doi:10.2147/tacg.s71506 · Cited by 51
Self-citationPeng, Y., Zhu, X., & Qiu, L. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.001 · Cited by 50
Dendrimer-Enabled Therapeutic Antisense Delivery Systems as Innovation in Medicine
Mignani, S. M., Shi, X., Zabłocka, M., & Majoral, J. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00385 · Cited by 50
Pharmacokinetic–Pharmacodynamic (PKPD) Analysis with Drug Discrimination
Negus, S. S., & Banks, M. L. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_36 · Cited by 46
Henry, S. P., Seguin, R. M., Cavagnaro, J. A., Berman, C., Tepper, J., & Kornbrust, D. J. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0593 · Cited by 42
Belfort, R., Da, G., Johnson, D. W., Mansour, S., Muccioli, C., Sheppard, J., Mora-Durate, J., Chan, C., Palestine, A., Perez, J. E. A., et al. (2002) · UCL Discovery (University College London) · Cited by 41
Geller, B. L., Li, L., Martinez, F. G., Sully, E. K., Sturge, C. R., Daly, S. M., Pybus, C. A., & Greenberg, D. E. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky058 · Cited by 41
Narayanan, P., Shen, L., Curtis, B. R., Bourdon, M. A., Nolan, J. P., Gupta, S., Hoffmaster, C. M., Zhou, F., Christian, B., Schaubhut, J., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy119 · Cited by 41
Sewing, S., Boess, F., Moisan, A., Bertinetti‐Lapatki, C., Minz, T., Hedtjaern, M., Tessier, Y., Schuler, F., Singer, T., & Roth, A. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159431 · Cited by 39
Juliano, R. L., Wang, L., Tavares, F. X., Brown, E., James, L. I., Ariyarathna, Y., Ming, X., Mao, C., & Suto, M. J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1320 · Cited by 39
Patient-customized oligonucleotide therapy for a rare genetic disease
Kim, J., Chen, H., Moufawad El Achkar, C., Black, L. E., Douville, J., Larson, A., Pendergast, M. K., Goldkind, S. F., Ea, L., Kuniholm, A., et al. (2020) · Yearbook of pediatric endocrinology · doi:10.1530/ey.17.14.8 · Cited by 39
Bosgra, S., Sipkens, J. A., de Kimpe, S. J., den Besten, C., Datson, N. A., & van Deutekom, J. C. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0805 · Cited by 34
Moisan, A., Gubler, M., Zhang, J. D., Tessier, Y., Erichsen, K. D., Sewing, S., Gérard, R., Avignon, B., Huber, S., Benmansour, F., et al. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.11.006 · Cited by 33
Stimuli‐Responsive Phosphorus‐Based Polymers
Teasdale, I. (2018) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201801077 · Cited by 33
Echevarría, L., Aupy, P., Relizani, K., Bestetti, T., Griffith, G., Blandel, F., Komisarski, M., Haeberli, A., Svinartchouk, F., Garcı́a, L., et al. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0773 · Cited by 31
Self-citationAupy, P., Echevarría, L., Relizani, K., Zarrouki, F., Haeberli, A., Komisarski, M., Tensorer, T., Jouvion, G., Svinartchouk, F., García, L., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.11.020 · Cited by 31
Self-citationGaranto, A., Duijkers, L., & Collin, R. W. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16035285 · Cited by 30
Self-citationHenry, S. P., Narayanan, P., Shen, L., Bhanot, S., Younis, H. S., & Burel, S. A. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2017.0666 · Cited by 30
Shen, L., Engelhardt, J. A., Hung, G., Yee, J., Kikkawa, R., Matson, J. E., Tayefeh, B., Machemer, T., Giclas, P. C., & Henry, S. P. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0584 · Cited by 28
Li, J., Ren, Y., Yin, Y., Ji, S., Zhou, S., Wang, L., Mou, Z.-Z., Li, L., Lu, W., & Zhou, T. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.55 · Cited by 28
Zhang, A., Uaesoontrachoon, K., Shaughnessy, C. J., Das, J. R., Rayavarapu, S., Brown, K. J., Ray, P. E., Nagaraju, K., van den Anker, J. N., Hoffman, E. P., et al. (2015) · Toxicology Reports · doi:10.1016/j.toxrep.2015.05.008 · Cited by 27
Polyphosphazenes for the delivery of biopharmaceuticals
Hsu, W., Csaba, N., Alexander, C., & García-Fuentes, M. (2019) · Journal of Applied Polymer Science · doi:10.1002/app.48688 · Cited by 24
Younis, H. S., Vickers, T. J., Levin, A. A., & Henry, S. P. (2006) · Journal of Immunotoxicology · doi:10.1080/15476910600718236 · Cited by 23
Cited by
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 828
Lauffer, M. C., van Roon-Mom, W., Aartsma-Rus, A., & Collaborative, N. =. 1. (2024) · Communications Medicine · doi:10.1038/s43856-023-00419-1 · Cited by 273
Self-citationGlycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?
Dowdy, S. F. (2023) · RNA · doi:10.1261/rna.079507.122 · Cited by 171
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli, M., Roy, S., Newell, R., Pestano, L., Dickinson, B., Rigby, K., Herazo-Maya, J., Jenkins, G., Ian, S., Saini, G., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104304 · Cited by 129
Metadata
- Authors
- Hammond, S. M., Aartsma‐Rus, A., Alves, S., Borgos, S. E., Buijsen, R. A. M., Collin, R. W. J., Covello, G., Denti, M. A., Desviat, L. R., Echevarría, L., Foged, C., Gaina, G., Garanto, A., Goyenvalle, A. T., Guzowska, M., Holodnuka, I., Jones, D. R., Krause, S., Lehto, T., Montolio, M., Van Roon‐Mom, W., & Arechavala‐Gomeza, V.
- Venue
- EMBO Molecular Medicine
- Published
- 2021-04-06
- Volume
- 13
- Issue
- 4
- Pages
- e13243-e13243
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3150397896
- Cited by
- 388
- References
- 204
- FWCI
- 15.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.